Company Biota Pharmaceuticals Inc Nasdaq
Equities
US6295191091
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
03-14 | Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-14 | Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024 |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oral Recombinant Protein Vaccines
100.0
%
| 0 | 100.0 % | 7 | 100.0 % | +6,796.26% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 7 | 100.0 % | +6,796.26% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sean Tucker
FOU | Founder | - | 31/12/03 |
Phillip Eric Lee
DFI | Director of Finance/CFO | 37 | 18/12/22 |
Michael Finney
CHM | Chairman | 65 | 30/06/07 |
James Cummings
CTO | Chief Tech/Sci/R&D Officer | - | 26/09/21 |
Chief Tech/Sci/R&D Officer | - | 30/08/22 | |
Edward Berg
LAW | General Counsel | - | 13/02/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Yedid
BRD | Director/Board Member | 66 | 24/10/19 |
Elaine Heron
BRD | Director/Board Member | 76 | 24/08/22 |
Michael Finney
CHM | Chairman | 65 | 30/06/07 |
Sean Tucker
FOU | Founder | - | 31/12/03 |
David Wheadon
BRD | Director/Board Member | 66 | 20/04/21 |
Director/Board Member | 73 | 03/08/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 177,345,031 | 174,833,551 ( 98.58 %) | 507,020 ( 0.2859 %) | 98.58 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-1.65% | 103B | |
+6.75% | 101B | |
+7.07% | 23.07B | |
-12.60% | 22.23B | |
-5.24% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |
- Stock Market
- Equities
- VXRT Stock
- Stock
- Company Biota Pharmaceuticals Inc